Harmony Biosciences Holdings, Inc.

Health Care
Biotechnology: Pharmaceutical Preparations
www.harmonybiosciences.com

Earnings Score
Moat Score
Safety Score

Market Cap $1.79B
PE 12
Debt $197.50M
Cash $453.27M
EV $1.54B
FCF $218.67M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	$145.49M
EBIT	$191.80M
ROE	22%
ROA	19%
FCF	$218.67M
Equity	$659.16M
Growth Stability	100%
PE	12.33
PEG	0.16
PB	2.72
P/FCF	8.21
P/S	2.51
Price/Cash	0.25
Debt/Equity	0.3
Debt/FCF	0.9
Net Margins	20%
Gross Margins	78%
Op. Margins	27%
Earnings CAGR	64%
Sales Growth YoY	20%
Sales Growth QoQ	8%
Sales CAGR	40%
FCF CAGR	19%
Equity CAGR	63%
Earnings Stability	-0.18
Earnings Growth YoY	86%
Earnings Growth QoQ	7%

Earnings CAGR 5Y	76%
Sales CAGR 5Y	42%
FCF CAGR 5Y	24%
Equity CAGR 5Y	64%
Earnings CAGR 3Y	32%
Sales CAGR 3Y	32%
FCF CAGR 3Y	23%
Equity CAGR 3Y	42%
Market Cap	$1.79B
Revenue	$714.73M
Assets	$999.20M
Total Debt	$197.50M
Cash	$453.27M
Shares Outstanding	56.83M
EV	1.54B
Earnings Score	6%
Moat Score	96%
Safety Score	96%
Final Score	66%
Working Capital	404.17M
Current Ratio	3.31
Gross Profit	$557.92M
Shares Growth 3y	-2%
Equity Growth QoQ	10%
Equity Growth YoY	41%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The companys product WAKIX pitolisant is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.

SEC Filings

Direct access to Harmony Biosciences Holdings, Inc. (HRMY) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Harmony Biosciences Holdings, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Harmony Biosciences Holdings, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 64%

Stability -18%

loading chart...

Harmony Biosciences Holdings, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Harmony Biosciences Holdings, Inc..

Years

Calculation mode

= $8.2B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$219M	$260M	$309M	$367M	$436M	$518M	$616M	$731M	$869M	$1B	$1.2B	$12B
DCF		$236M	$255M	$276M	$298M	$322M	$347M	$375M	$405M	$438M	$473M	$4.7B
Value	$8.2B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Net Margins	-3K%	-40%	11%	41%	22%	20%	20%
ROA	-	4%	20%	18%	24%	19%	19%
ROE	-	-66%	19%	45%	28%	22%	22%

Good Net Margins (20.36%)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Debt over FCF	-	-66.96	2.05	1.38	0.96	0.9	0.9
Debt over Equity	-0.23	2.06	1.08	0.5	0.45	0.3	0.3
Growth Stability	-	-	-	-	100%	100%	100%

Good Debt/FCF ratio (0.9)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Good Debt/Equity ratio (0.3)

The company is not overleveraged and has a good balance between equity and debt.

Good Graham’s Stability (100%)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	CAGR 5Y
Revenue YoY growth	-	3K%	91%	43%	33%	23%	42%
Earnings YoY growth	-	-66%	-154%	425%	-29%	13%	76%
Equity YoY growth	-	-123%	92%	116%	16%	41%	64%
FCF YoY growth	-	-96%	-3K%	47%	52%	-0%	24%